- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02715960
Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules
March 21, 2016 updated by: Yijing He, Central South University
In an early clinical research, 138 patients completed the treatment of Psoriasis Vulgaris by Acitretin Capsules in 8 weeks, the results indicate 75 cases effectively (54.3%),
50 cases invalid(36.2%), 13 cases serious(9.4%).
To investigate the influence of genetic factors on the curative effect and find the relationships between genetic variants and the response of Acitretin Capsules to treatment of Psoriasis Vulgaris.
Study Overview
Detailed Description
Investigators analyzed the various levels of genetic factors, including: 1.To analysis the key gene variants which associated with ADME affect the efficacy of Acitretin Capsules; 2.Direct full genetic sequencing of MHC genes, to explore the genetic variations of efficacy and side effects; 3. Direct sequencing of all exons in the gene in the patients of the response of serious and effectively, to explores the rare genetic variation may cause deterioration of treatment by Acitretin Capsules.
Study Type
Interventional
Enrollment (Anticipated)
500
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Recruiting
- Xiangya Hospital Central South University
-
Contact:
- Yijing He, MD, PhD
- Phone Number: +86-1587481262
- Email: yijinghe@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosed according to Classification criteria for Psoriasis vulgaris
- Patients aged 18 to 70 years (to the date of screening)
- PASI grade ≥7point
- Not treatment in the Topical corticosteroids, Immunosuppression, Biologicals agents or Tretinoin cream, Phototherapy nearly one months before enrolled.
- Total bilirubin < 1.5 x ULN, AST(SGOT)/ALT(SGPT) <2.5 x ULN if not liver metastases<5 x ULN if known liver metastases, Creatinine clearance <1.5 x ULN
- Understanding the whole process of the study, voluntary participation and signed the informed consent
Exclusion Criteria:
- Pregnant women, ready to pregnant or lactating women
- Have a serious heart, lung, kidney and other vital organs and endocrine system lesions and the history
- Patients is liver function abnormal persons (ALT above the center laboratory normal limit) or hepatitis b patient grain carriers
- Patients with chronic diarrhea, or peptic ulcer nearly 1 year
- Patients suffering from malignant tumor
- Patients suffering from acute and chronic infectious diseases
- Mental disorders, history of alcohol abuse, drug or other substance abuse
- Other cases which researchers believe that can not enroll
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single-arm
intervention: open registry, non-randomized, single-arm trial.
Acitretin Capsules: 2.5 per piece.
|
During The first treatment stage:10mg per day, 3 days,oral; The second stage: 20mg per day, 3 days,oral; The third stage: 30mg per day, and maintain this dose,oral.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
disease control rate
Time Frame: 8 weeks after the first treatment
|
8 weeks after the first treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Xiang Chen, MD, Xiangya Hospital of Central South University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2015
Primary Completion (Anticipated)
December 1, 2017
Study Completion (Anticipated)
December 1, 2017
Study Registration Dates
First Submitted
March 17, 2016
First Submitted That Met QC Criteria
March 21, 2016
First Posted (Estimate)
March 22, 2016
Study Record Updates
Last Update Posted (Estimate)
March 22, 2016
Last Update Submitted That Met QC Criteria
March 21, 2016
Last Verified
December 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016 AW/CSU/PS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
IPD Plan Description
data not entered
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis Vulgaris
-
LEO PharmaCompletedPlaque Psoriasis | Psoriasis VulgarisGermany
-
SoligenixRecruitingPsoriasis | Plaque Psoriasis | Psoriasis VulgarisUnited States
-
LEO PharmaTerminatedPsoriasis | Plaque Psoriasis | Psoriasis VulgarisBelgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
-
PRCL Research Inc.CompletedPlaque Psoriasis | Psoriasis VulgarisCanada, Slovakia, Ukraine
-
University Hospital, GhentBelgium Health Care Knowledge CentreNot yet recruiting
-
Chinese University of Hong KongNot yet recruitingPsoriasis Vulgaris
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University of California, San FranciscoNovartis Pharmaceuticals; National Psoriasis FoundationRecruitingPsoriasis VulgarisUnited States
-
Centre for Human Drug Research, NetherlandsJanssen PharmaceuticalsRecruiting
Clinical Trials on Acitretin Capsules
-
Xijing HospitalHenan Provincial People's Hospital; The First Affiliated Hospital of Dalian...Completed
-
Frankel, Amylynne, M.D.Stiefel, a GSK CompanyUnknownPsoriasisUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedNon-melanomatous Skin CancerUnited States
-
Cairo UniversityRecruitingDepression | Liver Diseases | Hyperlipidemias | XerosisEgypt
-
Istituti Fisioterapici OspitalieriUniversity of BolognaCompleted
-
Günther HofbauerUniversity of ZurichWithdrawn
-
South Valley UniversityCompleted
-
South Valley UniversityActive, not recruiting
-
University of Medicine and Dentistry of New JerseyConnetics Corp.CompletedPsoriasis
-
PfizerCompletedModerate to Severe PsoriasisKorea, Republic of